LIDODOSE- lidocaine hydrochloride gel 
Gensco Laboratories, LLC

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

----------

LidoDose Topical Anesthetic

Dosage and Administration

Adults and children 2 years of age and older: Apply using a gloved hand. Swirl the applicator tip prior to removing swab from the pouch and apply to area 3-5 minutes prior to procedure not more than 4 times daily.

Children under 2 years of age: consult a physician.

Usage

Pain relief

Warning: for external use only.

Methemoglobinemia


Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.


Signs and symptoms of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue LidoDose and any other oxidizing agents. Depending on the severity of the symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. More severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.

Avoid contact with eyes.

Stop use and consult a physician if condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days. Do not use in large quantities, particularly over raw surfaces or blistered areas.

DRUG INTERACTIONS

Patients that are administered local anesthetics may be at increased risk of developing methemoglobinemia when concurrently exposed to the following oxidizing agents:

Class Examples
Nitrates/Nitrites nitroglycerin, nitroprusside, nitric oxide, nitrous oxide
Local anesthetics benzocaine, lidocaine, bupivacaine, inepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine
Antineoplastic agents cyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea
Antibiotics dapsone, sulfonamides, nitrofurantoin, para¬aminosalicylic acid
Antimalarials chloroquine, primaquine
Anticonvulsants phenytoin, sodium valproate, phenobarbital
Other drugs acetaminophen, metoclopramide, sulfa drugs (i.e., sulfasalazine), quinine

Keep out of reach of children

If swallowed, get medical help or contact a Poison Control Center right away.

Storage

Store between 68 and 77 F (20 - 25 C), with allowed excursions between 59 and 86 F (15 - 30 C). Protect from freezing. (See USP Controlled Room Temperature).

PATIENT COUNSELING INFORMATION

Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.

Active Ingredients:

Lidocaine Hydrochloride 3%

Purpose:

Anesthetic

Inactive Ingredients:

Aqua (Deionized Water), Carbomer, Isopropyl Alcohol, Petrolatum, Polysorbate-20, Triethanolamine

Please see product insert for additional information.

LIDO DOSE

Carton
Insert
Label
LIDODOSE 
lidocaine hydrochloride gel
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:35781-0301
Route of AdministrationTOPICAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
LIDOCAINE HYDROCHLORIDE (UNII: V13007Z41A) (LIDOCAINE - UNII:98PI200987) LIDOCAINE HYDROCHLORIDE ANHYDROUS3 mg  in 100 mL
Inactive Ingredients
Ingredient NameStrength
WATER (UNII: 059QF0KO0R)  
CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) (UNII: 4Q93RCW27E)  
ISOPROPYL ALCOHOL (UNII: ND2M416302)  
PETROLATUM (UNII: 4T6H12BN9U)  
POLYSORBATE 20 (UNII: 7T1F30V5YH)  
TRIETHANANOLAMINE PHENYLBENZIMIDAZOLE SULFONATE (UNII: TQA10H23WC)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:35781-0301-525 in 1 BOX01/01/2018
1NDC:35781-0301-01 mL in 1 POUCH; Type 0: Not a Combination Product
2NDC:35781-0301-1100 in 1 BOX01/01/2018
2NDC:35781-0301-01 mL in 1 POUCH; Type 0: Not a Combination Product
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC monograph not finalpart34801/01/2018
Labeler - Gensco Laboratories, LLC (831042325)

Revised: 10/2022
Document Id: ea3b2c15-c1c6-c4ea-e053-2995a90a1dae
Set id: 0b3e8433-4f93-4f01-9df0-020fb6922bce
Version: 7
Effective Time: 20221004
 
Gensco Laboratories, LLC